Lyell Immunopharma's (LYEL) Neutral Rating Reiterated at HC Wainwright

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report)'s stock had its "neutral" rating reiterated by equities research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $1.00 price objective on the stock. HC Wainwright's target price would suggest a potential upside of 115.61% from the stock's previous close.

Lyell Immunopharma Price Performance

NASDAQ:LYEL traded up $0.03 during trading hours on Wednesday, reaching $0.46. 389,670 shares of the company traded hands, compared to its average volume of 1,040,689. Lyell Immunopharma has a 1-year low of $0.39 and a 1-year high of $2.88. The stock has a market cap of $136.95 million, a P/E ratio of -0.59 and a beta of -0.26. The firm's 50-day moving average is $0.57 and its 200-day moving average is $0.75.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The firm had revenue of $0.01 million during the quarter. As a group, research analysts predict that Lyell Immunopharma will post -0.78 earnings per share for the current year.

Insider Activity at Lyell Immunopharma

In related news, Director Richard Klausner purchased 158,000 shares of the firm's stock in a transaction on Friday, March 14th. The stock was purchased at an average price of $0.60 per share, for a total transaction of $94,800.00. Following the acquisition, the director now directly owns 843,365 shares in the company, valued at $506,019. The trade was a 23.05 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Sumant Ramachandra purchased 200,000 shares of the stock in a transaction that occurred on Friday, March 21st. The shares were purchased at an average cost of $0.58 per share, with a total value of $116,000.00. Following the completion of the acquisition, the director now owns 200,000 shares in the company, valued at approximately $116,000. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 768,640 shares of company stock worth $449,508. 25.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LYEL. Barclays PLC grew its position in shares of Lyell Immunopharma by 312.7% during the third quarter. Barclays PLC now owns 240,615 shares of the company's stock worth $332,000 after buying an additional 182,315 shares in the last quarter. Takeda Pharmaceutical Co. Ltd. bought a new position in shares of Lyell Immunopharma during the fourth quarter worth about $527,000. SG Americas Securities LLC grew its stake in Lyell Immunopharma by 102.8% in the fourth quarter. SG Americas Securities LLC now owns 116,748 shares of the company's stock worth $75,000 after purchasing an additional 59,182 shares in the last quarter. Jane Street Group LLC increased its holdings in Lyell Immunopharma by 63.7% in the third quarter. Jane Street Group LLC now owns 287,717 shares of the company's stock valued at $397,000 after buying an additional 111,917 shares during the last quarter. Finally, State Street Corp raised its stake in Lyell Immunopharma by 1.9% during the third quarter. State Street Corp now owns 3,889,553 shares of the company's stock valued at $5,368,000 after buying an additional 71,233 shares in the last quarter. Institutional investors and hedge funds own 66.05% of the company's stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.